ADVERTISEMENT
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
Suresh Ramalingam, MD, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, discussed results from the phase 3 LAURA study. Results demonstrated that administration of osimertinib after definitive chemoradiation improved progression-free survival (PFS) among patients with unresectable, stage 3, EGFR-mutated non-small cell lung cancer (NSCLC).
Source:
Ramalingam SS. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA4